美国急性呼吸衰竭支气管镜应用的时间趋势与变异
这是一项基于美国国家住院患者样本(覆盖全美97%住院)的观察性队列研究,纳入2012-2018年接受有创机械通气的成人住院患者6,101,070例,其中609,405例(约10%)接受了支气管镜。支气管镜使用率从2012年的9.5%(95%CI 9.1%-9.9%)升至2018年的10.8%(95%CI 10.4%-11.2%)(P<.001)。2018年1,787家医院中支气管镜使用率从0%到57.1%不等,调整患者和医院特征后,16.0%的变异归因于医院层面,中位OR为2.13(95%CI 2.05-2.21)。作者认为医院间巨大变异提示可能存在不恰当的实践差异,需要进一步研究明确哪些患者能从支气管镜中获益。
要点
- 2012-2018年接受有创机械通气的成人住院患者中,支气管镜使用率从9.5%(95%CI 9.1%-9.9%)升至10.8%(95%CI 10.4%-11.2%)(P<.001)。
- 2018年1,787家医院中支气管镜使用率从0%到57.1%不等,调整患者和医院特征后16.0%的变异归因于医院层面。
- 中位OR为2.13(95%CI 2.05-2.21),从低使用率医院转到高使用率医院接受支气管镜的 odds 增加113%。
- 接受支气管镜的住院患者平均年龄61岁,41.8%为女性,院内死亡率为30.8%。
- 作者认为医院间巨大变异提示可能存在不恰当的实践差异,需要进一步研究明确哪些患者能从支气管镜中获益。
适用人群与场景
- 2012-2018年美国国家住院患者样本中接受有创机械通气的成人住院患者,共6,101,070例。
研究设计与关键结果
- 研究类型:观察性队列研究,使用美国国家住院患者样本(覆盖全美97%住院),纳入2012-2018年接受有创机械通气的成人住院患者6,101,070例。
- 支气管镜使用情况:609,405例接受了支气管镜;接受支气管镜的患者平均年龄61岁,41.8%为女性,院内死亡率为30.8%。
- 时间趋势:支气管镜使用率从2012年的9.5%(95%CI 9.1%-9.9%)升至2018年的10.8%(95%CI 10.4%-11.2%)(P<.001 for difference)。
- 医院间变异:2018年1,787家医院中支气管镜使用率从0%到57.1%不等;多水平模型调整患者和医院特征后,16.0%的变异归因于医院层面。
- 中位OR为2.13(95%CI 2.05-2.21),从低使用率医院转到高使用率医院接受支气管镜的 odds 增加113%。
证据类型、等级与局限
- 证据类型:观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为医院间支气管镜使用的巨大变异提示可能存在不恰当的实践差异,需要进一步研究明确哪些患者能从支气管镜中获益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: National data on bronchoscopy for the evaluation of acute respiratory failure are lacking, and the limited available data suggest wide variation in use.
RESEARCH QUESTION: How commonly is bronchoscopy performed among hospitalizations with acute respiratory failure? How has use changed over time and across hospitals?
STUDY DESIGN AND METHODS: This was an observational cohort study of adult hospitalizations (2012-2018) treated with invasive mechanical ventilation (IMV) using the National Inpatient Sample, which represents 97% of all hospitalizations in the United States. We measured the proportion of hospitalizations treated with IMV who underwent bronchoscopy and assessed trends in bronchoscopy use over time. Multilevel linear regression models were used to quantify hospital-level variation, adjusting for differences in patient and hospital characteristics.
RESULTS: We identified 6,101,070 IMV-treated hospitalizations (2012-2018), of whom 609,405 underwent bronchoscopy; among hospitalizations receiving bronchoscopy, mean age was 61 years, 41.8% were women, and in-hospital mortality was 30.8%. The percentage of IMV-treated hospitalizations receiving bronchoscopy increased from 9.5% (95% CI, 9.1%-9.9%) in 2012 to 10.8% (95% CI, 10.4%-11.2%) in 2018 (P < .001 for difference). In 2018, bronchoscopy use varied from 0% to 57.1% among 1,787 hospitals, and in multilevel models adjusted for patient and hospital characteristics, 16.0% of the variation was explained at the hospital level. The median OR was 2.13 (95% CI, 2.05-2.21), indicating 113% increased odds of receiving bronchoscopy if moving from a lower-use to a higher-use hospital.
INTERPRETATION: Bronchoscopy use among hospitalizations treated with IMV has increased over time. The large variation in use of bronchoscopy across hospitals suggests potentially unwarranted practice variation and need for further studies to clarify which patients benefit from bronchoscopy.
参考来源
- Wayne MT, Valley TS, Arenberg DA, et al. Temporal Trends and Variation in Bronchoscopy Use for Acute Respiratory Failure in the United States. Chest. 2022. PMID: 36007595. doi:10.1016/j.chest.2022.08.2210
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。